Yale University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).

1,492 total trials 254 currently recruiting 1005 completed early-phase tilt top decile by trial count

Yale University: 1,492 sponsored US clinical trials, 254 recruiting.

Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.

Top-decile sponsor footprint

Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 60/100

1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,492 total, page 23 of 30

COMPLETED Early Phase 1

The Effects of ∆-9-THC and Naloxone in Humans

NCT01591629

COMPLETED

Plasma Angiopoietin Levels in Children Following Cardiopulmonary Bypass

NCT01489475

TERMINATED Phase 1

Novel Treatments to Enhance Smoking Cessation Before Cancer Surgery: Effects on Smoking and Surgical Outcomes

NCT01479998

COMPLETED Phase 2

Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer

NCT01523457

COMPLETED

Yale Pink and Blue Kids: Effects of Exposure During Pregnancy to Nicotine or Antidepressants in 4-8 Year Old Children

NCT01640600

COMPLETED Phase 1

Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis

NCT01456468

COMPLETED NA

A Randomized Controlled Trial of Routine Shave Margins Versus Standard Partial Mastectomy in Breast Cancer Patients

NCT01452399

COMPLETED NA

Screening to Augment Referral to Treatment- Project START

NCT01539525

COMPLETED NA

Chronic Alcohol, Stress Inflammatory Response and Relapse Risk

NCT02193204

COMPLETED Phase 2

Tobacco Approach Avoidance Training for Adolescent Smokers-1

NCT01625767

COMPLETED NA

Using Capnography to Reduce Hypoxia During Pediatric Sedation

NCT01463527

COMPLETED NA

Cognitive Enhancement as a Target for Cocaine Pharmacotherapy

NCT01531153

COMPLETED NA

Study to Evaluate the Health and Wellness Policies of the New Haven Public School District.

NCT02043626

COMPLETED Phase 2

The Effect of Sorafenib on Portal Pressure

NCT01714609

COMPLETED NA

Emergency Department (ED) Disability Diagnostic Tool

NCT01416857

COMPLETED NA

Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia

NCT01462227

COMPLETED NA

Effectiveness and Cost Effectiveness of Peer Mentors in Reducing Hospital Use

NCT01566513

COMPLETED

Genetics of Fatty Liver Disease in Children

NCT01966627

COMPLETED

Acute Coronary Syndrome and Care-Seeking Delay: A Web Based Behavioral Study

NCT01407146

COMPLETED Phase 2

Efficacy and Tolerability of Riluzole in Treatment Resistant Depression

NCT01204918

COMPLETED Phase 2

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

NCT01367002

COMPLETED

Evaluation of the Effect of Hypoglycemia With PET and a Norepinephrine Transporter Ligand

NCT02056249

COMPLETED Phase 1

Fathers for Change for Men With Co-occurring Domestic Violence and Substance Abuse

NCT01385553

COMPLETED Phase 2

Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma

NCT01319422

COMPLETED NA

Sleep Apnea in TIA/Stroke: Reducing Cardiovascular Risk With Positive Airway Pressure

NCT01446913

COMPLETED NA

Study to Investigate Benefits of Weight Loss in Young Adults and Adolescents

NCT01901978

COMPLETED NA

Cognitive-Behavioral Therapy for Irritability in Adolescents With High Functioning Autism Spectrum Disorder

NCT01631851

COMPLETED

Limit Computed Tomography (CT) Scanning in Suspected Renal Colic

NCT01352676

COMPLETED NA

An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia

NCT01355952

COMPLETED NA

Facts-Up-Front Versus Traffic-Light Food Labels

NCT01626729

COMPLETED Phase 3

Family Health and Development Project

NCT01567969

COMPLETED

The Relationship Between Positive End Expiratory Pressure and Cardiac Index in Patients With Acute Respiratory Distress Syndrome (ARDS) Managed on a Fluid Protocol

NCT01714583

COMPLETED Phase 2

Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention

NCT01227044

COMPLETED Phase 1

Cognitive-Behavioral Therapy for Pain and Opioid Dependence in Methadone Maintenance Treatment

NCT01334580

COMPLETED NA

Calcitonin for Treating X-linked Hypophosphatemia

NCT01652573

COMPLETED Phase 1

Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations

NCT01246401

COMPLETED Phase 1

Effects of Transcranial Direct Current Stimulation on Tobacco Withdrawal Symptoms

NCT01567982

COMPLETED NA

Absorbable Suture Versus Tissue Glue to Repair Defects Following Mohs Surgery

NCT01298167

COMPLETED NA

Progesterone for Postpartum Cocaine Relapse

NCT01249274

COMPLETED Phase 1

Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors

NCT01625611

COMPLETED Phase 1

A Smoking Cessation Treatment for Adult Women

NCT01422239

COMPLETED Phase 1

Alcohol Counseling for Telephone Quitline Callers

NCT01120080

COMPLETED Phase 3

Lifestyle, Exercise and Nutrition Study 1

NCT02109068

COMPLETED

Hepatic De Novo Lipogenesis (DNL)in the Pathogenesis of Hepatic Steatosis in Obese Youth

NCT01725035

COMPLETED Phase 2

Cognitive Remediation and Work Therapy in the Initial Phase of Substance Abuse Treatment

NCT01410110

COMPLETED NA

Smoking Cessation for Smokers With Sleep Problems

NCT01277887

COMPLETED NA

Treating Low-Income Smokers in the Hospital Emergency Department

NCT01328431

COMPLETED

Hydronephrosis on Ultrasound With CT Finding in Patients With Renal Colic

NCT01349244

COMPLETED Phase 1

Decreasing Stress and Improving Self-control With "Stress in Control" (Sync) Training

NCT01721499

COMPLETED NA

Randomized Trial of Parent Training for Young Children With Autism

NCT01233414

← Previous Page 23 of 30 Next →

Phase Distribution

PhaseTrial count
Phase 1 312
Phase 2 267
Phase 3 52
Phase 4 47

What is open in the Yale University pipeline

254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).

Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).

Top condition: Opioid Use Disorder (19 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Yale University: open-pipeline peers nationwide

Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Yale UniversityWashington University School of MedicineJohns Hopkins UniversityUniversity of PennsylvaniaNovartis PharmaceuticalsNYU Langone HealthCSL BehringPenn State UniversityUniversity of Hawaii
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,492 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this Yale University page

1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.

  • 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.